Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT04844385Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival Rate at 18 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04844385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844385.